CLPT
ClearPoint NeuroCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-20
Current thesis
The bull read after earnings is that CLPT delivered record revenue, 16% organic total growth, 25% organic device growth, higher gross margin, and maintained a full-year revenue outlook while pointing to IRRAS revenue and cost synergies in 2H26 [#8-K-2026-05-13].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -8.6.
What can break
Growth depends in part on partner clinical, regulatory, and funding progress across the biopharma pipeline, which management does not fully control [#10-Q-2026-05-13].
Momentum
87
Value
37
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $17.00 · Bear $7.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $28.33
Why
Momentum87 · Δ7d -8.6
Value37 · Δ7d -0.0
Sentiment38 · Δ7d +8.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
87
26% active weight
Current posture
7d trendSoftening
Δ7d
-8.6
Δ21d
-9.5
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
38
34% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+11.5
Why this grade
Composite grade C. Momentum 87.2 / Value 36.5 / Sentiment 38.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$451.34M
Beta
1.02
Shares Out
29.99M
P/E (TTM) · Derived
-16.7
P/S (TTM)
12.30
P/FCF (TTM) · Derived
-16.29
Rev YoY
+42.9%
EPS YoY
+48.7%
Gross Margin
+61.8%
Op Margin
-66.2%
Net Debt
$12.31M
Current Ratio
5.79
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology